Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 26 March 2018, 12:36 HKT/SGT
Share:
    

Source: Hitachi, Ltd.
Mitsubishi Tanabe Pharma and Hitachi Utilize AI Technology
to Begin Collaborative Creation for Improving Efficiency of Clinical Trials
for New Drug Development

Aiming to shorten the period of clinical trial and reduce development cost, and improve the probability of successful new drug development

TOKYO, Mar 26, 2018 - (JCN Newswire) - Mitsubishi Tanabe Pharma Corporation (TSE: 4508) and Hitachi, Ltd. (TSE: 6501) today announced that they have initiated collaborative creation for improving the efficiency of clinical trials for the development of new drugs. The companies undertake a wide range of operations to make clinical trials more efficient overall, using Hitachi's advanced digital technology such as AI(1), aiming to shorten the period for development of new drugs and reduce development cost, while improving the probability of successful development.

The business environment surrounding pharmaceutical companies in Japan is expected to become increasingly severe given the lowering of drug prices and the substantial increase of the market share of generics. For the business to achieve continued growth, a review of the process for the fast development of new drugs that satisfy unmet medical needs(2) is required. In particular, clinical trials in which new drugs are administered to humans for evaluating efficacy and safety as well as possible side-effects are an important process for the successful development of new drugs. However, since the elaborate design of a trial plan is needed, a huge amount of time and the know-how as well as the experience of skilled experts are necessary.

To meet these challenges, Mitsubishi Tanabe Pharma and Hitachi focused on the fact that a lot of time is spent searching and collecting information from technical knowledge in medicine such as medical papers and ClinicalTrials.gov(3) in the planning stage of clinical trials, and the two companies began considering automated information search and collection jointly at the beginning of 2017. By utilizing AI technology such as natural language processing and deep learning(4), which the Research & Development Group of Hitachi has developed for medical use, the companies have confirmed that the time spent collecting information is shortened by about 70% when compared with conventional operations, which depend on the know-how of skilled experts, while the accuracy of the data collected and organized is also verified, so that the companies have obtained a perspective on the feasibility of full-scale use.

Mitsubishi Tanabe Pharma and Hitachi have initiated collaborative creation for making a wide range of operations related to the entire clinical trial process more efficient. Mitsubishi Tanabe Pharma, with a corporate philosophy of that "We contribute to the healthier lives of people around the world through the creation of pharmaceuticals," has long been involved in the research and development of pharmaceuticals, having an advantage in its extensive medical knowledge and wide ranging capabilities for drug discovery. Meanwhile, Hitachi utilizes the knowledge and experience that it has accumulated as a manufacturer over many years, and the digital solution created by its IoT platform "Lumada," undertaking the social innovation business to provide solutions to the issues of its clients. The two companies use their technology and know-how, collaboratively working on improving the efficiency of clinical trials by using an array of advanced digital technologies, including AI. In addition, the companies plan to expand the scope of their collaborative creation in the future to undertake a wide range of demonstration experiments.

As a first step, Hitachi will roll out a solution of automated technology for collection of information from medical literature to the pharmaceutical industry in Japan and overseas starting in 2018. This automated solution will be developed through collaborative creation with utilization of Hitachi's IoT platform, "Lumada."

(1) AI: Artificial Intelligence
(2) Unmet medical needs: medical needs for disease, for which no effective treatment is available.
(3) ClinicalTrials.gov: Database that provides information on ongoing clinical trials and clinical research through the US National Library of Medicine(NLM), which is jointly run by the National Institute of Health(NIH) and the Food and Drug Administration(FDA) in the United States.
(4) Deep learning: Machine learning method using a multi-layer deep neural network.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation is a research-driven pharmaceutical company based in Osaka Japan. Mitsubishi Tanabe Pharma is taking on the challenge of drug discovery in the fields of autoimmune disorders, central nervous system diseases, diabetes and kidney diseases, and vaccines. To those ends, the Company is strengthening its R&D pipeline. Mitsubishi Tanabe Pharma contributes to the healthier lives of people around the world through the creation of pharmaceuticals. https://www.mt-pharma.co.jp/e.


About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society's challenges, combining its operational technology, information technology, and products/systems. The company's consolidated revenues for fiscal 2017 (ended March 31, 2018) totaled 9,368.6 billion yen ($88.4 billion). The Hitachi Group is an innovation partner for the IoT era, and it has approximately 307,000 employees worldwide. Through collaborative creation with customers, Hitachi is deploying Social Innovation Business using digital technologies in a broad range of sectors, including Power/Energy, Industry/Distribution/Water, Urban Development, and Finance/Social Infrastructure/Healthcare. For more information on Hitachi, please visit the company's website at http://www.hitachi.com.

Contact:
Hitachi Ltd
Corporate Communications
Tel: +81-3-3258-1111


Mar 26, 2018 12:36 HKT/SGT
Source: Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501)

Topic: Press release summary
Sectors: Electronics, Enterprise IT, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.


Hitachi, Ltd. Links

http://www.hitachi.com

https://www.facebook.com/hitachi.global/

https://twitter.com/hitachiglobal?lang=en

https://www.youtube.com/user/HitachiBrandChannel

https://ph.linkedin.com/company/hitachi

Hitachi, Ltd.
Oct 23, 2018 09:22 HKT/SGT
Hitachi Appoints Partners to Support Wylfa Newydd
Oct 22, 2018 06:45 HKT/SGT
Demonstration of Hitachi ICT System verifies Efficiencies in Energy and Medical IT Operations at New Delhi AIIMS Hospital
Oct 16, 2018 13:43 HKT/SGT
Hitachi's Heavy Ion Beam Therapy System Starts Treatment at Osaka Heavy Ion Therapy Center
Oct 12, 2018 14:00 HKT/SGT
Daikin and Hitachi Start Joint Demonstration Aiming to Digitalize Quality Control Know-How in Reaction Process of Chemical Manufacturing
Oct 12, 2018 07:09 HKT/SGT
Hitachi to Establish New Company to Foster Human Resource for the Global Rollout of the Social Innovation Business Using Digital Technologies
Oct 4, 2018 11:29 HKT/SGT
Hitachi Launches AI-Assisted Predictive Maintenance Service for Petrochemical Plants
Oct 3, 2018 14:23 HKT/SGT
Hitachi Held Global Women's Summit 2018 to Promote the Activities of Female Employees
Oct 2, 2018 07:00 HKT/SGT
Hitachi Announces Merger of Hitachi Consumer Marketing and Hitachi Appliances to Handle Home Appliance and A/C Businesses
Sept 25, 2018 16:45 HKT/SGT
NEDO and Hitachi to Start Cloud-Based Advanced Energy Management System Demonstration Project in Slovenia
Sept 18, 2018 17:02 HKT/SGT
Hitachi: Ansaldo STS Receives Contract for the Operation and Maintenance Services of Lines 3, 4, 5 & 6 of Riyadh Metro
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: